Biogaia AB
BIOG B
ISIN SE0017769995 / Valor 118922125
Biogaia AB
UMushroom community rating:
About company
BioGaia AB, established in 1990, is a Swedish healthcare company that specializes in the development, production, and distribution of probiotic dietary supplements. Recognized globally for its expertise in probiotics, BioGaia has forged a reputation as a pioneer in the field, leveraging extensive networks of independent researchers, manufacturing specialists, and distribution partners to bring its products to market. The company's offerings are endorsed by pediatricians and healthcare professionals worldwide, reflecting its commitment to quality and efficacy. BioGaia's products are available in over 100 countries, underscoring its position as a leading entity in the probiotic supplements industry. Through its dedication to innovation and collaboration, BioGaia continues to contribute significantly to the global healthcare landscape, particularly in the realm of dietary supplements.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (17.10.2025):
Biogaia AB reported its financial results for the second quarter of 2025, showing a 5% increase in net sales to SEK 404.7 million compared to the same period last year. While the Pediatrics segment experienced modest growth, the Adult Health segment demonstrated strong performance. However, operating profits declined due to increased marketing investments. The company also announced strategic initiatives to expand its global footprint.
Net Sales Growth
Biogaia AB achieved net sales of SEK 404.7 million in Q2 2025, reflecting a 5% increase compared to SEK 384.1 million in Q2 2024. Year-to-date net sales rose by 5% to SEK 771.0 million from SEK 753.9 million, excluding foreign exchange effects.
Segment Performance
The Adult Health segment saw a significant increase in net sales, up 15% to SEK 89.8 million in Q2 2025 and 20% year-to-date to SEK 184.4 million. In contrast, the Pediatrics segment experienced a modest growth of 2% in Q2 2025 to SEK 310.1 million, while year-to-date sales slightly declined by 3% to SEK 580.0 million.
Operating Profit Decline
Operating profits decreased by 20% to SEK 108.3 million in Q2 2025 from SEK 135.4 million in the previous year, resulting in an operating margin of 27% compared to 35%. Year-to-date operating profit also fell by 26% to SEK 205.5 million.
Increased Marketing Investments
The decline in operating profit is attributed to a 23% increase in operating expenses for Q2 2025, reaching SEK 185.5 million. Year-to-date operating expenses rose by 31% to SEK 356.8 million, driven by enhanced marketing efforts and the expansion of direct sales channels.
Strategic Expansion
Following the end of Q2 2025, Biogaia AB launched a subsidiary, BioGaia New Sciences AB, to advance its microbiome research and establish direct sales in the Netherlands. Additionally, the company converted 1,038,202 Class A shares into Class B shares, resulting in a decrease in the number of voting shares.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1094 M
Market cap (USD)
113,929
Daily traded volume (Shares)
111.6 / 109.5
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
